Drugs News and Research

RSS

China Sky third quarter total revenue decreases 16.3% to $36.2 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced financial results for the third quarter of 2010.

8 Nov 2010

$Beta blockers for high blood pressure also reduce fracture risk: Study$

Beta blockers for high blood pressure also reduce fracture risk: Study

Beta blockers, one of the most commonly used types of cardiovascular drugs, taken by about 20 per cent of the population, have been found to cut a person's incidence of bone fracture by half. This new and welcome side effect was reported by Professor Tuan Nguyen from Sydney's Garvan Institute of Medical Research and his Australian-based colleagues. “Indeed, we found that men and women who used beta-blockers had a 50 per cent lower risk of fracture than those not using beta blockers… We were very excited about the finding because, as you know, a lot of elderly people use beta blockers ... it’s a very significant public health issue,” he said.

8 Nov 2010

Eli Lilly to acquire Avid Radiopharmaceuticals

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that partner company Avid Radiopharmaceuticals, Inc. has signed a definitive merger agreement to be acquired by Eli Lilly and Company.

8 Nov 2010

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Ardea Biosciences, Inc. announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol.

8 Nov 2010

CytRx reports $4.4 million net loss for third quarter 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2010, and provided a business update. The Company also announced the filing of a shelf registration statement with the Securities and Exchange Commission to replace its existing shelf registration, which expires in December 2010.

8 Nov 2010

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

In advance of the 41st Union World Conference, the Global Alliance for TB Drug Development (TB Alliance) today announced the launch of the first clinical trial to test a novel tuberculosis regimen in a new development paradigm designed to speed new treatments to patients. This novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by shortening and simplifying treatment worldwide.

8 Nov 2010

22nd Century awarded $244,000 QTDP program grant

22nd Century Limited, LLC, a company focused on smoking cessation and tobacco harm reduction products, announced that it has been awarded $244,000 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies commonly used to treat rheumatoid arthritis have been found to potentially reduce the risk of developing Alzheimer's dementia among people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Industry experts speculate, strategize on what election means for business and reform

The Wall Street Journal: "Health-care companies see the Republican win as a chance to chip away at aspects of Mr. Obama's health overhaul least favorable to the industry. Insurance companies, drug manufacturers and hospitals say they will press to peel away the law's new taxes on health-care companies, pass tougher medical malpractice curbs and knock down a new board that recommends Medicare spending cuts" (Adamy, 11/3).

8 Nov 2010

Research findings on RGL2 protein can lead to new therapeutic target for pancreatic cancer

One of the most frustrating problems faced by doctors who treat pancreatic cancer is the lack of effective therapeutic options. More than 38,000 people in the United States die of the disease each year, and new drugs and treatments are desperately needed.

8 Nov 2010

MitoSciences awarded $244,000 grant under IRS Qualifying Therapeutic Discovery Project

MitoSciences Inc. today announces that it has been awarded a $244,000 grant under the IRS Qualifying Therapeutic Discovery Project. This award was made in support of MitoSciences' efforts to develop the world's most advanced set of assays for unlocking the role of metabolism in cancer and other critical diseases, and for helping researchers to design and monitor the most effective therapies for those conditions.

8 Nov 2010

Scientists identify genes that enable some immune systems to halt HIV; finding could spur drug, vaccine development

Tiny variants in a protein that alerts the body to infection could explain how one in 300 HIV-infected people are able to resist the onset of AIDS for years without needing any treatment, researchers said Thursday in a study published online in the journal Science, Agence France-Presse reports

8 Nov 2010

Prophylaxis can prevent postoperative nausea and vomiting

Vomiting is unpleasant. Nearly 30% of all patients suffer from nausea and vomiting after surgery. The financial repercussions of this are longer patient stays in the recovery room, with increased need for personnel. Appropriate prophylaxis and treatment can prevent postoperative nausea and vomiting. In a systematic review of the literature, Dirk Rüsch and co-authors investigate how treatment recommendations for nausea after general anesthesia can be improved.

8 Nov 2010

Risk pools, drug prices and other issues in health law implementation

A health law program that directs $5 billion for coverage of otherwise uninsurable people through state-run high-risk insurance pools has attracted only 8,011 people according to health department enrollment figures, The New York Times reports. That's a paucity compared to the hundreds of thousands of people government actuaries predicted would flock to the program causing it to run out of money too early.

8 Nov 2010

People with SLE more likely to develop hematologic malignancies

People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Statin drugs do not benefit pediatric lupus patients

Lupus puts children at higher risk for coronary artery disease when they become adults, but routinely using statins doesn't provide enough benefit to warrant their regular use in children and adolescents, according to the largest study of pediatric lupus patients to date.

8 Nov 2010

Synergy receives $244,479 grant under QTDP program to develop plecanatide for gastrointestinal disorders

Synergy Pharmaceuticals, Inc. a developer of new drugs to treat gastrointestinal disorders (GI) and diseases, announced today that it has been awarded a $244,479 grant under the Qualifying Therapeutic Discovery Project (QTDP) program to aid the Company in its development of plecanatide currently in clinical development to treat gastrointestinal disorders.

8 Nov 2010

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.

8 Nov 2010

Leaders discuss best practices, challenges for detecting counterfeit medications

During the opening of the 10th annual meeting of the International Society of Pharmacovigilance (ISoP) in Accra, Ghana, the country's "Vice President John Dramani Mahama on Wednesday called on member countries of the society to institute effective measures that would help detect fake and counterfeit drugs," Ghana News Agency reports.

8 Nov 2010

Drugs News and Research

China Sky third quarter total revenue decreases 16.3% to $36.2 million

Beta blockers for high blood pressure also reduce fracture risk: Study

Eli Lilly to acquire Avid Radiopharmaceuticals

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

CytRx reports $4.4 million net loss for third quarter 2010

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

22nd Century awarded $244,000 QTDP program grant

Study suggests bacterial products contribute to autoimmune diseases

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Industry experts speculate, strategize on what election means for business and reform

Research findings on RGL2 protein can lead to new therapeutic target for pancreatic cancer

MitoSciences awarded $244,000 grant under IRS Qualifying Therapeutic Discovery Project

Scientists identify genes that enable some immune systems to halt HIV; finding could spur drug, vaccine development

Prophylaxis can prevent postoperative nausea and vomiting

Risk pools, drug prices and other issues in health law implementation

People with SLE more likely to develop hematologic malignancies

Statin drugs do not benefit pediatric lupus patients

Synergy receives $244,479 grant under QTDP program to develop plecanatide for gastrointestinal disorders

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

Leaders discuss best practices, challenges for detecting counterfeit medications

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News